TABLE II.

Efficacy outcomes from select histologic analyses of patients with advanced non-small-cell lung cancer treated with taxane-containing regimens

Reference	Histologic subtype	Regimen	os(months)			hr	95% ci	orr (%)	95% ci	or	95% ci
			Pts (n)	Median	95% ci
Scagliotti et al., 200957,a
	Squamous		187	11.9	nr	nr		nr		nr
	Adenocarcinoma		310	8.8	nr
	Large cell		54	9.5	nr
	Other		65	10.6	nr
Tan et al., 200961
	Squamous
		Vinorelbine–cisplatin	65b	8.9	6.4 to 12.8	nr		24.6		nr
		Docetaxel–cisplatin	64b	9.8	8.4 to 12.2			29.1
	Adenocarcinoma
		Vinorelbine–cisplatin	79b	11.7	8.7 to 16.5			28.1
		Docetaxel–cisplatin	75b	11.6	9.7 to 15.7			22.7
Treat et al., 201033
	Squamous
		Gemcitabine–carboplatin	67	6.6	5.1 to 9.5	1.4	0.93 to 1.99	25.4	15.5 to 37.5	0.40c	0.18 to 0.88
		Gemcitabine–paclitaxel	74	10.2	7.7 to 13.7	1.1	0.75 to 1.55	35.1	24.4 to 47.1	0.65	0.31 to 1.33
		Paclitaxel–carboplatin	61	10.3	8.7 to 12.0	Reference		45.9	33.1 to 59.2	Reference
	Nonsquamous
		Gemcitabine–carboplatin	67	8.2	7.3 to 9.5	0.96	0.81 to 1.13	25.3	20.6 to 30.5	0.93	0.65 to 1.34
		Gemcitabine–paclitaxel	74	8.4	7.2 to 9.8	0.97	0.82 to 1.14	31.4	26.2 to 36.9	1.3	0.88 to 1.77
		Paclitaxel–carboplatin	61	8.3	7.3 to 9.8	Reference		26.7	22.0 to 32.0	Reference

^aValues reflect the combined treatment arms (patients received gemcitabine–cisplatin, paclitaxel–carboplatin, or vinorelbine–cisplatin).

^bReflects enrolled patients; number of evaluable patients was not given.

^cp < 0.05.

Pts = patients; os = overall survival; ci = confidence interval; hr = hazard ratio; orr = overall response rate; or = odds ratio; nr = not reported.